Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodie...

Celý popis

Podrobná bibliografie

Vydáno v:	Clinical cancer research Ročník 26; číslo 5; s. 984
Hlavní autoři:	Autio, Karen A, Boni, Valentina, Humphrey, Rachel W, Naing, Aung
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.03.2020
Témata:	Animals Antibodies, Monoclonal - therapeutic use B7-H1 Antigen - antagonists & inhibitors CTLA-4 Antigen - antagonists & inhibitors Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - pathology Drug-Related Side Effects and Adverse Reactions - prevention & control Humans Immunotherapy - adverse effects Neoplasms - drug therapy Neoplasms - immunology Prodrugs - therapeutic use Programmed Cell Death 1 Receptor - antagonists & inhibitors
ISSN:	1557-3265, 1557-3265
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!